Page last updated: 2024-10-25

r 59022 and Lymphoproliferative Disorders

r 59022 has been researched along with Lymphoproliferative Disorders in 2 studies

R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist

Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Velnati, S1
Ruffo, E2
Massarotti, A1
Talmon, M1
Varma, KSS1
Gesu, A1
Fresu, LG1
Snow, AL2
Bertoni, A1
Capello, D1
Tron, GC1
Graziani, A2
Baldanzi, G2
Malacarne, V1
Larsen, SE1
Das, R1
Patrussi, L1
Wülfing, C1
Biskup, C1
Kapnick, SM1
Verbist, K1
Tedrick, P1
Schwartzberg, PL1
Baldari, CT1
Rubio, I1
Nichols, KE1

Other Studies

2 other studies available for r 59022 and Lymphoproliferative Disorders

ArticleYear
Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    Topics: Cell Death; Computer Simulation; Diacylglycerol Kinase; Drug Evaluation, Preclinical; Humans; Lympho

2019
Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1.
    Science translational medicine, 2016, Jan-13, Volume: 8, Issue:321

    Topics: Animals; CD8-Positive T-Lymphocytes; Cell Death; Cytokines; Diacylglycerol Kinase; Gene Silencing; H

2016